Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Finnish sauna heat exposure induces stronger immune cell than cytokine responses.

Temperature (Austin, Tex.)·2026
Same author

Macrophage Polarization and Spatial Architecture Characterize the Tumor Immune Microenvironment and Prognosis in Hepatoblastoma.

The American journal of pathology·2026
Same author

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

bioRxiv : the preprint server for biology·2026
Same author

Prolonged Systemic Inflammatory Response Syndrome Predicts Atrial Fibrillation After Cardiac Surgery.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same author

Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors.

Angewandte Chemie (International ed. in English)·2026
Same author

Uncomplicated and Complicated Acute Appendicitis Induce Different Cytokine Patterns.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026

Related Experiment Video

Updated: Jul 11, 2025

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
08:08

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation

Published on: July 8, 2011

20.5K

Dimeric IgA specifically disables intracellular mutated oncodrivers.

Stuart Prince1, Maija Hollmén1

  • 1MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.

Immunity
|November 15, 2023
PubMed
Summary

Antibody therapy can now target intracellular cancer proteins. Researchers show dimeric-IgA antibodies can neutralize and remove mutated oncodriver proteins inside epithelial cancer cells, challenging previous immunotherapy beliefs.

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.1K

Related Experiment Videos

Last Updated: Jul 11, 2025

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
08:08

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation

Published on: July 8, 2011

20.5K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.1K

Area of Science:

  • Immunotherapy
  • Cancer Biology
  • Molecular Medicine

Background:

  • Prevailing immunotherapy dogma posits antibody therapy is limited to extracellular antigens.
  • Targeting intracellular oncoproteins remains a significant challenge in cancer treatment.

Purpose of the Study:

  • To investigate the potential of transcytosing dimeric-IgA antibodies for targeting intracellular oncodriver proteins.
  • To demonstrate the therapeutic efficacy of antibody-mediated intracellular antigen removal in epithelial cancers.

Main Methods:

  • Utilized pIgR-dependent, transcytosing dimeric-IgA antibodies.
  • Administered antibody treatment to models of epithelial cancer.
  • Assessed targeting, neutralization, and removal of intracellular mutated oncodriver proteins.

Main Results:

  • Demonstrated successful targeting and neutralization of intracellular mutated oncodriver proteins.
  • Showcased effective removal of these proteins from within epithelial cancer cells.
  • Provided evidence against the limitation of antibody therapy to extracellular targets.

Conclusions:

  • pIgR-dependent dimeric-IgA antibodies offer a novel strategy for intracellular cancer immunotherapy.
  • This approach overcomes the traditional barrier of targeting extracellular antigens, expanding therapeutic possibilities.
  • The findings pave the way for new treatments for epithelial cancers driven by intracellular mutations.